{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:58:46Z","timestamp":1785477526076,"version":"3.56.0"},"reference-count":15,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":210,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Case Reports in Oncological Medicine"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) are increasingly used in oncologic clinical practice, leading to a corresponding rise in immune\u2010related adverse events (irAEs). In this context, we present a case of fulminant ICI\u2010associated encephalitis (ICI\u2010encephalitis) presenting within 24\u2009h after a single administration of nivolumab (a PD\u20101 inhibitor), in a patient with recurrent Hodgkin lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>After receiving outpatient nivolumab combined with brentuximab (an antibody\u2013drug conjugate), the patient presented with altered mental status, status epilepticus, and abnormal signal in the bilateral temporal lobes as shown on brain magnetic resonance imaging (MRI). Lumbar puncture found pleocytosis and slight elevation in protein; there was no evidence of abnormal autoantibodies or pathogenic infection. Following multidisciplinary consultation, the patient was ultimately diagnosed with ICI\u2010encephalitis and began on empiric treatment with intravenous methylprednisolone dosed 1\u2009g\/day for 5 days, followed by 5 days of intravenous immunoglobulin (IVIG). The patient experienced resolution of electrographic seizures and gradual improvement of mental status toward baseline but had persistent short\u2010term memory loss and did not experience complete brain MRI recovery. Ultimately, hospice placement was pursued after goals of care discussions with the patient\u2032s spouse, and the patient expired within 1 month of discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case serves as a safety signal for rapidly presenting ICI\u2010encephalitis following nivolumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1155\/crom\/6122845","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:11:03Z","timestamp":1785474663000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fulminant Immune Checkpoint Inhibitor\u2010Related Encephalitis (ICI\u2010Encephalitis) Presenting Rapidly After First Infusion of Nivolumab: A Case Report"],"prefix":"10.1155","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0543-9229","authenticated-orcid":false,"given":"Jonathan","family":"Markle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9551-4762","authenticated-orcid":false,"given":"Alyson","family":"Auriemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Rushlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Eickhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9004-638X","authenticated-orcid":false,"given":"Charles","family":"Bane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"e_1_2_11_1_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00600-w"},{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104595"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.58"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05328-3"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012122"},{"key":"e_1_2_11_6_2","unstructured":"CARE Case Report Guidelines CARE Case Report Guidelines Accessed April 13 2025 https:\/\/www.care-statement.org."},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-7146"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.824511"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.001"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2752-5"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2020.20377"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.1912"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.6439"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.4102\/sajr.v22i1.1310"}],"container-title":["Case Reports in Oncological Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crom\/6122845","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/crom\/6122845","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crom\/6122845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:11:11Z","timestamp":1785474671000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/crom\/6122845"}},"subtitle":[],"editor":[{"given":"Lipi","family":"Buch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/crom\/6122845"],"URL":"https:\/\/doi.org\/10.1155\/crom\/6122845","archive":["Portico"],"relation":{},"ISSN":["2090-6706","2090-6714"],"issn-type":[{"value":"2090-6706","type":"print"},{"value":"2090-6714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-11-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"6122845"}}